Trading Cockpit

· checking…
Loading…
← CockpitCompetitor Analysis › IVA.PA Inventiva SAOpen in the cockpit ↗

Inventiva SAIVA.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Biotechnology
Momentum weak 29
Competitor Analysis ▸ ChartsOpen in the cockpit
Mkt cap
$912M
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$2.12M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.0%
Hurdle
n/a
no reverse DCF
Next earnings
145 days
31 Mar 2027
Close · EUR€3.40
1D+1.2%
1W+6.9%
1M+21.4%
3M-16.9%
6M-28.8%
YTD-13.8%
1Y+4.3%
ATR %7.3%
52w lowhigh45.2% off high

What Inventiva does

Employees: 77

Inventiva at a glance

Size Inventiva (IVA.PA) is a France Health Care company (Biotechnology) with a market value of $912M, the 145th largest of 206 France companies the cockpit tracks. Shares closed at €3.40 on 6 Nov 2026.

Performance Over six months the shares fell 28.8%, against -12.2% for the median peer and -0.4% for the France market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue fell 99.6% over the last twelve months (peer median +0.6%); the operating margin is -307,063.3% (peer median -24.8%).

Valuation It trades at 14,560.9× enterprise value to sales against a peer median of 7.1× (most expensive of 19).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010011 May 202611 Aug 20266 Nov 2026Peer median 89IVA.PA 71
Six months, rebased to 100: Inventiva against the median of its 20 peers (local-currency closes).

Inventiva financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€49,000€4.48M€9.20M€17.5M€12.2M
Revenue growth—-51%-47%+44%—
Gross profit-€2.56M€1.57M€5.61M€14.9Mn/a
EBITDA-€148M-€133M-€95.9M-€105M-€61.0M
Net income-€248M-€354M-€184M-€110M-€54.3M
Free cash flow-€110M-€105M-€86.3M-€82.2M-€45.5M
Capital expenditure€358,000€247,000€333,000€540,000€561,000
Total debtn/a€59.4M€54.3M€37.4M€34.5M

Quarterly statements and history in the cockpit →

Inventiva competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%GLUE9887OXBJBIO6001952160MGTXSNDX4587PRMEANRO688253VSTM301333301520IVA.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Inventiva is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%+4,000%0×5,000×10,000×15,000×GLUEODTXMGTXVSTMIVA.PARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Inventiva is the large dot.

Inventiva competitors and peer comparison

How Inventiva compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Inventiva against its 20 peers (data as of 6 Nov 2026)
MeasureIVA.PAPeer medianRank in peer set
1-month return+21.4%-5.4%2nd highest of 21
6-month return-28.8%-12.2%6th lowest of 20
Distance from 52-week high-45.2%-40.0%6th lowest of 21
Revenue growth (TTM)-99.6%+0.6%lowest of 18
Operating margin-307,063.3%-24.8%lowest of 19
EV / Sales14,560.9×7.1×most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Inventiva IVA.PAFrance$912M-29%-100%-307,063%14,560.9×n/an/a
Monte Rosa Therapeutics GLUEUnited States$902M-45%-84%-633%11.1×n/an/a
Odyssey Therapeutics ODTXUnited States$924Mn/a-33%-5,415%208.9×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$927M-54%n/a-108%26.5×n/an/a
Oxford BioMedica OXB.LUnited Kingdom$892M-14%+16%-18%4.3×n/an/a
Jade Biosciences JBIOUnited States$958M-42%n/an/an/an/an/a
China Animal Husbandry Industry 600195.SSChina$960M-17%+1%2%1.4×6.6%+4.4%
GNI 2160.TJapan$866M-29%+10%-24%5.7×n/an/a
MeiraGTx MGTXUnited States$864M-8%+948%46%2.1×-9.9%+39.2%
Syndax Pharmaceuticals SNDXUnited States$859M-56%+160%-62%3.5×n/an/a
Peptidream 4587.TJapan$856M-10%+1%-25%6.6×n/an/a
Prime Medicine PRMEUnited States$843M+45%-18%-4,825%211.3×n/an/a
Alto Neuroscience ANROUnited States$987M+4%n/an/an/an/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$995M-11%0%22%4.7×11.1%+2.3%
Changchun BCHT Biotechnology 688276.SSChina$1.00B-11%+2%-29%10.0×n/an/a
Innovita Biological Technology 688253.SSChina$1.02B-4%-28%11%16.3×42.9%-16.6%
Wuhan Keqian Biology 688526.SSChina$814M-19%-22%20%4.7×8.8%+2.4%
Verastem VSTMUnited States$1.02B+72%+3,996%-183%11.1×n/an/a
R&G PharmaStudies 301333.SZChina$803M-12%+21%11%3.9×20.1%+11.8%
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$803M+91%-15%-8%17.9×48.8%+14.7%
Beijing SL Pharmaceutical 002038.SZChina$793M-21%-4%-119%7.6×-12.3%-10.9%

Questions

Which companies are Inventiva's closest peers?
The cockpit's peer set: Monte Rosa Therapeutics (GLUE), Odyssey Therapeutics (ODTX), Nanjing Leads Biolabs (9887.HK), Oxford BioMedica (OXB.L), Jade Biosciences (JBIO), China Animal Husbandry Industry (600195.SS), GNI (2160.T), MeiraGTx (MGTX).
Is Inventiva expensive compared with its peers?
On ev / sales it trades at 14,560.9× against a peer median of 7.1×, most expensive of 19 in its peer set.
How has Inventiva stock performed?
Over six months to 6 Nov 2026 the shares returned -28.8% against -12.2% for the median peer; over one year +4.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.